nach oben

Current Diabetes Reports

Erschienen in:

01.11.2017 | Therapies and New Technologies in the Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor)

Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes

verfasst von: Carla Greenbaum, Sandra Lord, Dana VanBuecken

Erschienen in: Current Diabetes Reports | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review seeks to characterize emerging concepts related to disease-modifying therapy in type 1 diabetes.

Recent Findings

We begin by describing the new understanding that islet autoimmunity, as identified by the presence of islet autoantibodies, inevitably leads to clinical type 1 diabetes. This understanding informs the new staging paradigm for type 1 diabetes, which suggests that type 1 diabetes may be recognized and diagnosed long before symptoms develop. Although it is known that nearly all individuals with established islet autoimmunity will eventually develop symptomatic type 1 diabetes (T1D), individual characteristics such as age and biomarker profile may predict rate of disease progression and response to treatment and may therefore be used to individualize therapy.

Summary

Key research supports the use of immunotherapy in TID, although a paradigm shift is necessary before immunotherapy may transition from clinical trials to clinical practice. Recent and ongoing research as it relates to these concepts is described throughout.

Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med. 1988;319(10):599–604.CrossRefPubMed

Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, Landais P, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med. 1988;318(11):663–70.CrossRefPubMed

Stiller CR, Laupacis A, Dupre J, Jenner MR, Keown PA, Rodger W, et al. Cyclosporine for treatment of early type I diabetes: preliminary results. N Engl J Med. 1983;308(20):1226–7.PubMed

Type 1 diabetes: stage 1. [Image on the Internet]. C2017. Available from https://trialnet.org/t1d-facts/stages-of-t1d/stage-1.

•• Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964–74. This scientific statement redefined diagnostic criteria for T1D, suggesting that individuals found to have multiple autoantibodies may be characterized as being in “Stage 1” of the disease. Almost all individuals in stage 1 of T1D will eventually progress to symptomatic diabetes. CrossRefPubMedPubMedCentral

Ziegler AG, Rewers M, Eisenbarth G, Simell O. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. J Am Med Assoc. 2013;309(23):2473–9.CrossRef

• Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, et al. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care. 2015;38(10):1975–85. This study shows that the risk of progression from autoantibody positivity to stage 3 (symptomatic) T1D varies based on age, with those at younger ages at greater risk of rapid progression of disease. This may justify the use of different therapies for the pediatric at-risk population versus the adult population. CrossRefPubMedPubMedCentral

Mahon JL, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C, et al. The TrialNet natural history study of the development of type 1 diabetes: objectives, design, and initial results. Pediatr Diabetes. 2009;10(2):97–104.

American Diabetes Association I. American Diabetes Association standards of medical Care in Diabetes 2017. Diabetes Care. 2017;40(Supplement 1):S1–S134.CrossRef

10.

Kostraba JN, Gay EC, Cai Y, Cruickshanks KJ, Rewers MJ, Klingensmith GJ, et al. Incidence of insulin-dependent diabetes mellitus in Colorado. Epidemiology. 1992;3(3):232–8.CrossRefPubMed

11.

Group EAS, Group EASS. Familial risk of type I diabetes in European children. Diabetologia. 1998;41(10):1151–6.CrossRef

12.

Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet. 1996;59(5):1134.PubMedPubMedCentral

13.

Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med. 2009;360(16):1646–54.CrossRefPubMed

14.

Hagopian S, Erlich H, Lernmark A, JinXiong S. The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. Pediatr Diabetes. 2011;12(8):133–43.CrossRef

15.

Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes. 2012;61(8):2066–73.CrossRefPubMedPubMedCentral

16.

Parikka V, Näntö-Salonen K, Saarinen M, Simell T, Ilonen J, Hyöty H, et al. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia. 2012;55(7):1926–36.

17.

Insel RA, Dunne JL, Ziegler AG. General population screening for type 1 diabetes: has its time come? Curr Opin Endocrinol Diabetes Obes. 2015;22(4):270–6.CrossRefPubMed

18.

TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr Diabetes. 2007;8(5):286–98.

19.

Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):412–9.CrossRefPubMedPubMedCentral

20.

Orban T, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care. 2014;37(4):1069–75.CrossRefPubMedPubMedCentral

21.

Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, et al. B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care. 2014;37(2):453–9.CrossRefPubMedPubMedCentral

22.

Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, et al. Anti-thymocyte globulin/G-CSF treatment preserves beta cell function in patients with established type 1 diabetes. J Clin Invest. 2015;125(1):448–55.CrossRefPubMed

23.

Gitelman SG, Gottlieb PA, Rigby MR, et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2013;1(4):306–16.CrossRefPubMed

24.

Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361(22):2143–52.CrossRefPubMed

25.

Hagopian W, Ferry RJ, Sherry N, Carlin D, Bonvini E, Johnson S, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized placebo-controlled Protégé trial. Diabetes. 2013;62(11):3901–8.CrossRefPubMedPubMedCentral

26.

Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015;125(8):3285–96.CrossRefPubMedPubMedCentral

27.

Sosenko JM, Skyler JS, Palmer JP, Krische JP, Liping Y, Mahon J, et al. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care 2013;36(9):2615–20.

28.

Vehik K, Cuthbertson D, Ruhlig H, Schatz DA, Peakman M, Krischer JP, et al. Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial. Diabetes Care. 2011;34(7):1585–90.CrossRefPubMedPubMedCentral

29.

Skyler J. Update on worldwide efforts to prevent type 1 diabetes. Ann N Y Acad Sci. 2008;1150:190.CrossRefPubMedPubMedCentral

30.

(NIDDK) NIoDaDaKD. Oral insulin for prevention of diabetes in relatives at risk for type 1 diabetes mellitus. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2017 Mar 31].Available from: https://clinicaltrials.gov/show/NCT00419562NLMIdentifier:NCT00419562.

31.

Bottazzo G, Lorin-Christensen A, Doniach D. Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet. 1974;2:1279–83.CrossRefPubMed

32.

Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, et al. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009;132(2):166–73.CrossRefPubMedPubMedCentral

33.

Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013;62(11):3766–74.CrossRefPubMedPubMedCentral

34.

Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013;56(2):391–400.CrossRefPubMed

35.

Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352(25):2598–608.CrossRefPubMed

36.

Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia. 2010;53(4):614–23.CrossRefPubMed

37.

Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013;1(4):284–94.CrossRefPubMedPubMedCentral

38.

Group DPTS. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346(22):1685–91.CrossRef

39.

Sosenko JMPJ, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Matheson D, Skyler JS. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the diabetes prevention trial-type 1. Diabetes Care. 2008;31(11):2188–92.CrossRefPubMedPubMedCentral

40.

(NIDDK) NIoDaDaKD. Teplizumab for prevention of type 1 diabetes in relatives “at-risk”. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2017 Mar 31].Available from: http://clinicaltrials.gov/show/ NCT01030861 NLM Identifier: NCT01030861.

41.

(NIDDK) NIoDaDaKD. ATG-GCSF in new onset type 1 diabetes. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2017 March 31].Available from: http://clinicaltrials.gov/show/ NCT02215200 NLM Identifier:NCT02215200.

42.

Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372(9):803–13.CrossRefPubMedPubMedCentral

43.

Health M. Trial of intranasal insulin in children and young adults at risk of type 1 diabetes (INITII). ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2017 March 31] Available from: http://clinicaltrials.gov/show/ NCT00336674 NLM Identifier:NCT00336674.

44.

University L. Diabetes Prevention - Immune Tolerance (DIAPREV-IT). ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2017 April 13] Available from: http://clinicaltrials.gov/show/ NCT01122446 NLM Identifier: NCT01122446.

45.

University L. Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and vitamin D3 to Children With Multiple Islet Autoantibodies (DiAPREV-IT2). ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2017 April 13] Available from: http://clinicaltrials.gov/show/ NCT02387164 NLM Identifier: NCT02387164.

46.

(NIDDK) NIoDaDaKD. CTLA4-Ig (abatacept) for prevention of abnormal glucose tolerance and diabetes in relatives at-risk for type 1. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2017 March 31].Available from: http://clinicaltrials.gov/show/ NCT01773707 NLM Identifier:NCT01773707.

47.

Bluestone J. T1DM Immunotherapy Using Polyclonal Tregs + IL-2 (TILT). In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2017 April 13] Available from: http://clinicaltrials.gov/show/ NCT02772679 NLM Identifier: NCT02772679.

48.

Tao B, Pietropaolo M, Atkinson M, Schatz D, Taylor D. Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method. PLos One. 2010;5(7):e11501.CrossRefPubMedPubMedCentral

49.

Miller RG, Secrest A, Sharma RK, Songer TJ, Orchard TJ. Improvements in the life expectancy of type 1 diabetes: the Pittsburge Epidemiology of Diabetes Complications study cohort. Diabetes. 2012;61(11):2987–92.

Titel: Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes
verfasst von: Carla Greenbaum
Sandra Lord
Dana VanBuecken
Publikationsdatum: 01.11.2017
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 11/2017
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-017-0932-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes